Tag: CVI

first-in-human

First-in-human patients continue to benefit from VenoValve at average of three...

Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...

I-Vasc announces €1.8 million Series A investment to launch its Velex...

I-Vasc, developer of the Velex device with its empty vein ablation (EVA) technology for the treatment of chronic venous insufficiency (CVI), has announced the...

AVF 2022: Emerging autogenous venous valve formation system sees “continual improvement”

An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...